As I said in my talk, I was inspired to give this presentation when I saw the one a friend of mine gave in Europe a few years ago.

As promised, below  is the YouTube of  Gábor Erdösi’s video presentation I mentioned in my talk. It goes into more detail than I was able to cover due to time constraints, and I’m sure you’ll find it fascinating.

Gábor has an extensive bibliography he has generously allowed me to make available to you.  Click here to retrieve it from my Dropbox.

This is the video I discussed about the deep dive into GLP-1 should you want much, much more information.

Also, I’ve put a couple of comprehensive papers in my Dropbox you can access here.  These, along with Gábor’s bibliography should give you a start on the study of incretins and the incretin effect.

Here is a recent update by one of the most noted incretin researchers:

Diabetes, Obesity and Metabolism (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.

Here are the two papers I discussed near the end on the weight loss effects of the GLP-1 agonist semaglutide;

Nature (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial:

Diabetes, Obesity and Metabolism (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

As many of you probably know, I write a weekly newsletter called The Arrow on Substack that is read by almost 10,000 people. If interested, you can sign up below: